Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMZKGPV)

Drug Name	Gemigliptin DMZKGPV
Synonyms	911637-19-9; UNII-5DHU18M5D6; 5DHU18M5D6; (S)-1-(2-Amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; (S)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; Gemigliptin [INN]; Gemigliptin (prop.INN); SCHEMBL1262740; CHEMBL3707235; CHEBI:134731; ZINC68245464; AKOS025290873; PB11419; DB12412; API0013914; AK170799; 2-Piperidinone, 1-((2S)-2-amino-4-(5,8-dihydro-2,4-
Drug Type	Small molecular drug
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Type-2 diabetes	DIS3X247	5A11	Phase 3	[1]
Diabetic complication	DIS4S2FC	5A2Y	Phase 3	[2]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01990469) Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin. U.S. National Institutes of Health.